Literature DB >> 30707294

[Treatment effects and cost-effectiveness of interdisciplinary multimodal pain treatment of patients with back pain : A controlled observational intervention study based on claims data and survey data of participants].

C J Wagner1, G Ayyad2, A Otzdorff2, K Bienek3, U Marnitz4, B von Pickardt5, W Seidel6, S Sehlen2, P Supantia2, G Lindena7.   

Abstract

BACKGROUND: Persons insured by AOK Nordost statutory health insurance (SHI) and on sick leave underwent a 20-day program of interdisciplinary multimodal pain therapy (IMST) following an initial assessment (IA). We evaluated its effectiveness regarding sick leave, utilization/costs of SHI services, and patient-reported characteristics of pain.
MATERIALS AND METHODS: Participants with >14 days of IMST in 2013-2015 and with data necessary for comparison (intervention group, IG) were matched 1:1 in 2 steps. From AOK Nordost data, we identified a comparison group (CG) having characteristics matching exactly and by propensity score. Starting on the IA (IG) or a comparable reference day (CG), we analyzed utilization/costs of services related to back pain for 365 days. Participants' characteristics of pain were surveyed on the IA day and within 183-365 days.
RESULTS: The 86 IG patients had on average 44.33 (median 12) days of sick leave less than the CG after their initial sick leave starting at the IA (significant, p <0.05). Fewer IG patients had ≥1 hospitalization (OR 0.33; 95%CI 0.12-0.88), ≥1 prescription of physiotherapy (OR 0.35; 95%CI 0.24-0.82), and ≥1 specialist visit (OR 0.39; 95%CI 0.10-0.52) related to back pain. More IG patients had "lasting absence of treatment" (OR 4.06; 95%CI 1.09-15.1). Follow-up interviews were available for 56 IG patients, showing less pain intensity, impairment by pain, and pain severity (significant). Regarding the SHI perspective, cost savings per patient nearly covered the IA and IMST costs. DISCUSSION: For a selected comparable population treated by protocol, IA and IMST was associated with reduction or "lasting absence" of treatment, pain relief, and major savings on sickness benefits. Other than in previous studies we found coverage of IA and IMST costs without consideration of productivity loss.

Entities:  

Keywords:  Chronic pain; Cost-of-illness; Integrated care; Pain severity according to von Korff; Sick leave

Mesh:

Year:  2019        PMID: 30707294     DOI: 10.1007/s00482-019-0356-4

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  14 in total

1.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

Review 2.  [Multidisciplinary assessment for multimodal pain therapy. Indications and range of performance].

Authors:  H-R Casser; B Arnold; T Brinkschmidt; I Gralow; D Irnich; K Klimczyk; B Nagel; M Pfingsten; M Schiltenwolf; R Sittl; W Söllner
Journal:  Schmerz       Date:  2013-08       Impact factor: 1.107

Review 3.  Multidisciplinary rehabilitation for chronic low back pain: systematic review.

Authors:  J Guzmán; R Esmail; K Karjalainen; A Malmivaara; E Irvin; C Bombardier
Journal:  BMJ       Date:  2001-06-23

4.  Treatment- and cost-effectiveness of early intervention for acute low-back pain patients: a one-year prospective study.

Authors:  Robert J Gatchel; Peter B Polatin; Carl Noe; Margaret Gardea; Carla Pulliam; Judy Thompson
Journal:  J Occup Rehabil       Date:  2003-03

5.  Does early intervention with a light mobilization program reduce long-term sick leave for low back pain: a 3-year follow-up study.

Authors:  Eli Molde Hagen; Astrid Grasdal; Hege R Eriksen
Journal:  Spine (Phila Pa 1976)       Date:  2003-10-15       Impact factor: 3.468

6.  Costs of back pain in Germany.

Authors:  Christina M Wenig; Carsten O Schmidt; Thomas Kohlmann; Bernd Schweikert
Journal:  Eur J Pain       Date:  2008-06-03       Impact factor: 3.931

7.  [Interdisciplinary treatment. Long-lasting, effective, and cost-effective].

Authors:  B Nagel; J Korb
Journal:  Orthopade       Date:  2009-10       Impact factor: 1.087

8.  [Evaluation of a multimodal pain therapy at the University Pain Centre Dresden].

Authors:  A Schütze; U Kaiser; U Ettrich; K Grosse; G Gossrau; M Schiller; K Pöhlmann; K Brannasch; R Scharnagel; R Sabatowski
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

9.  [Multimodal integrated assessment and treatment of patients with back pain. Pain related results and ability to work].

Authors:  U Marnitz; L Weh; G Müller; W Seidel; K Bienek; G Lindena; A Gussek
Journal:  Schmerz       Date:  2008-08       Impact factor: 1.107

10.  ["Back pain coach". A project for patients with back pain].

Authors:  G Lindena; U Marnitz; P Hartmann; G Müller
Journal:  Schmerz       Date:  2012-12       Impact factor: 1.107

View more
  4 in total

1.  [Quality and effectiveness of interdisciplinary multimodal pain therapy].

Authors:  M Pfingsten; U Kaiser; R Sabatowski
Journal:  Schmerz       Date:  2019-12       Impact factor: 1.107

Review 2.  [Cross-sectoral interdisciplinary multimodal pain therapy : Recommendations on structural and process parameters of the ad hoc commission "Interdisciplinary Multimodal Pain Therapy" of the German Pain Society (Deutsche Schmerzgesellschaft e.  V.)].

Authors:  M Pfingsten; B Arnold; A Böger; T Brinkschmidt; H-R Casser; D Irnich; U Kaiser; K Klimczyk; J Lutz; M Schiltenwolf; D Seeger; B Zernikow; R Sabatowski
Journal:  Schmerz       Date:  2019-06       Impact factor: 1.107

3.  A cross-sectional study to validate an administrative back pain severity classification tool based on the graded chronic pain scale.

Authors:  M Hochheim; P Ramm; M Wunderlich; V Amelung
Journal:  Sci Rep       Date:  2022-10-08       Impact factor: 4.996

4.  Cost-effectiveness analysis of a chronic back pain multidisciplinary biopsychosocial rehabilitation (MBR) compared to standard care for privately insured in Germany.

Authors:  M Hochheim; P Ramm; M Wunderlich; V Amelung
Journal:  BMC Health Serv Res       Date:  2021-12-24       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.